Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice
- 1 July 2013
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 335 (2), 463-471
- https://doi.org/10.1016/j.canlet.2013.03.002
Abstract
No abstract availableFunding Information
- National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2012BA139B02)
- National Science and Technology Major Project of the Ministry of Science and Technology of China (2012ZX09301001-006)
This publication has 44 references indexed in Scilit:
- Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer PatientsClinical and Developmental Immunology, 2012
- Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritisCytokine, 2012
- The IL-33/ST2 pathway — A new therapeutic target in cardiovascular diseasePharmacology & Therapeutics, 2011
- NF-κB in immunobiologyCell Research, 2011
- Resolution of Allergic Inflammation and Airway Hyperreactivity Is Dependent upon Disruption of the T1/ST2–IL-33 PathwayAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel 'Alarmin'?PLOS ONE, 2008
- IL-33 reduces the development of atherosclerosisThe Journal of Experimental Medicine, 2008
- Inflammation and Cancer: A Double-Edged SwordCancer Cell, 2007
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factorin vivoProceedings of the National Academy of Sciences of the United States of America, 2007